Media Coverage

Quest Diagnostics Inc. (Quest), an American diagnostic information service provider, has reportedly announced that it has inked an agreement to acquire the laboratory services business unit belonging to Boyce and Bynum Pathology Laboratories (BBPL), a clinical & diagnostic laboratory service provider.

Parts of Boyce and Bynum Pathology Labs are set to be acquired by Quest Diagnostics. Quest announced they recently signed an agreement to acquire the assets of Boyce and Bynum's clinical laboratory services.

Quest Diagnostics announced today that it will build a 250,000-square-foot flagship laboratory in Clifton, New Jersey. The new laboratory will become the largest of the more than 20 major laboratory facilities in the Quest network and will employ more than 1,100 people. It is expected to be operational in early 2021.

The questions sound familiar: “Describe a time when you went above and beyond;” “Tell me about a time when you had to deliver bad news to a customer.” But in this telephone job interview, there is a twist: No human is on the other end of the line. Major companies such as laboratory-test provider Quest Diagnostics Inc., hospital operator HCA Healthcare Inc. and insurer Allstate Insurance Co. use such interviews for some hiring, as do retailers, restaurant chains and law firms.

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it has signed a definitive agreement to acquire the assets of the clinical laboratory services business of Boyce and Bynum Pathology Laboratories (BBPL), a leading provider of diagnostic and clinical laboratory services in the Midwest.

A new mass spectrometry blood test from Quest Diagnostics aims to provide physicians with an easy tool for assessing insulin resistance as an early predictor of future diabetes. The test, called the Cardio IQ Insulin Resistance Panel with Score, has been offered for about two months through Quest and is performed at Quest's Nichols Institute in San Juan Capistrano, California.

Jeffrey Gudin, M.D., is director of pain and palliative care at Englewood Hospital and Medical Center in New Jersey and a medical adviser for Quest Diagnostics. The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act, also known as the SUPPORT Act, is now the law of the land. This comprehensive, bipartisan bill, which aims to address the prolonged national opioid crisis, offers a rare opportunity to applaud progress in the national effort to address one of the great health care epidemics of our time: misuse of opioids and other prescription drugs. But there is still much more work to be done.

The Marin Healthcare District has sold its four outpatient clinical laboratories where blood is drawn for tests to Quest Diagnostics, a publicly-traded company based in Secaucus, New Jersey. The acquisition will double the number of labs Quest operates in Marin to eight. The Marin Healthcare District labs sold are located at 100 A Drake’s Landing, Greenbrae; 5 Bon Air Road, Larkspur; 23 Reed Blvd., Mill Valley; and 75 Rowland Way, Novato. Terms of the sale were not disclosed.

Developing novel approaches to understand pre-disease and health is the cornerstone strategy of One Brave Idea™, a research initiative led by Dr. Calum MacRae, vice chair for Scientific Innovation in the department of Medicine at Brigham and Women's Hospital. n a move to advance the ground-breaking work to identify coronary heart disease at the earliest transition from wellness to disease, Quest Diagnostics will contribute biomarker implementation, population health analytics and a national lab platform as a pillar supporter of One Brave Idea, the research initiative co-founded by the American Heart Association (AHA) and Verily Life Sciences with significant support from AstraZeneca.

Quest Diagnostics now supports Apple's health records feature, making it the second clinical testing laboratory to join the project. Early in 2018, the iPhone maker released plans to integrate patient health records — including allergies, immunizations and lab results — into its Health app as part of the iOS 11.3 beta rollout.